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Introduction 
Brain natriuretic peptide (BNP) is a relatively 
recent addition to the family of natriuretic peptides 
(1). Although originally isolated from the porcine 
brain, BNP, like atria1 natriuretic peptide (ANP), is a 
cardiac hormone which is synthesized and secreted 
into the circulation by the heart (1,2). Increased 
cardiac secretion of BNP has been reported in 
patients with predominant left-sided heart failure 
(2,3). No information is available for patients with 
haemodynamic alterations limited to the pulmonary 
circulation for BNP, although plasma ANP concen- 
trations have been shown to be elevated in pul- 
monary hypertension (4,5). We report measurement 
of plasma BNP concentrations in two patients with 
pulmonary hypertension undergoing right heart car- 
diac catheterizations. The patients were maintained 
on oxygen during the study as hypoxaemia can 
cause ANP release (6). We also report the effect of 
nifedipine, a calcium antagonist and potent vaso- 
dilator, on plasma BNP levels in one of these 
patients. 
Case 1 
A 57-year-old female was referred to our hospital 
with a 3-yr history of progressive fatigue and increas- 
ing dyspnoea with recent onset of ankle swelling. Her 
medical history was unremarkable. Physical exami- 
nation revealed peripheral cyanosis, a right ventricu- 
lar heave and a loud pulmonary component to the 
second heart sound. Investigations included a normal 
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chest radiography, hypoxaemia (arterial blood gases 
at rest, breathing room air: PaO, 6.8 kPa, PaCO, 
3.6 kPa), raised haemoglobin (18.8 g dl~ ‘) and 
reduced carbon monoxide gas transfer (0.59 mmol 
min-’ kPa- ’ l- *; predicted 1.51) with normal 
dynamic lung volumes. No auto-antibodies were 
detected and a ventilation-perfusion scan of the 
lungs was normal. On echocardiography, the right 
atrium and ventricle were grossly dilated with poor 
function. The left heart dimensions and functions 
were normal. Primary pulmonary hypertension was 
diagnosed. Right heart cardiac catheterization dem- 
onstrated raised pulmonary artery pressure (systolic 
81 mmHg, diastolic 39 mmHg) with no interatrial or 
interventricular shunt. Venous blood samples (20 ml) 
were collected into chilled tubes containing edetic 
acid and 4000 kallikrein inhibitory units of aprotonin 
(Bayer plc., Newbury, U.K.) for measurement of 
plasma BNP and ANP after resting in the supine 
position for 30 min (baseline) and also 60 min follow- 
ing 10 mg nifedipine administered sublingually. 
Plasma was assayed for BNP and ANP by radioim- 
munoassay after extraction, as previously described 
by our group (3). Baseline plasma BNP and ANP in 
this patient were 28.0pmol 1 - ’ and 23.1 pmol I- ’ 
respectively. For illustrative comparison, plasma 
BNP and ANP were also measured in five healthy 
subjects (two males) aged 49-54 years and they were 
3.2 f 0.2pmol 1~ ’ and 7.0 f. 2.1 pmol 1 - ’ respec- 
tively. Simultaneous measurement of pulmonary vas- 
cular resistance and the effect of nifedipine on plasma 
BNP and ANP are shown in Table 1. Oxygen satu- 
ration during catheterization, measured using a pulse 
oximeter, was maintained at a constant 98% with 
high flow oxygen. Systemic blood pressure was 
unchanged at 116/90 mmHg. Plasma ANP and BNP 
were also measured 2 h after the procedure and were 
27.3 pmol 1~ ’ and 37.2 pmol 1 - ’ respectively. 
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Table I Pulmonary vascular resistance and plasma ANP and BNP in a patient with primary 
pulmonary hypertension: effect of sublingual nifedipine 10 mg 
Time 
(min) 
PAP Cardiac Plasma Plasma 
systolic/diastolic output PVR A PVR BNP ANP 
(mm%9 (1 min - ‘) (dyn s cm m5) (“AI) (pm01 1~ ‘) (pm01 1-r) 
0 
(baseline) 
60 min 
(post-nifedipine 
10 w) 
81/39 3.5 1166 0 28 23.1 
85139 4.25 960 - 18 29.5 34.9 
PAP, pulmonary arterial pressure; PVR, pulmonary vascular resistance as calculated by 
pulmonary mean arterial pressure ~ pulmonary wedge pressure, divided by cardiac index, then 
multiplied by 79.9. 
Case 2 
A 52-year-old female was referred with a 2-month 
history of exertional dyspnoea and mild ankle 
swelling. In her medical history, she had extensive 
psoriasis for which she had only used topical agents. 
Examination showed cyanosis, a split second heart 
sound, pansystolic murmur of tricuspid regurgi- 
tation, pulsatile hepatomegaly and ankle swelling. 
Chest radiography revealed an enlarged heart with 
prominent pulmonary arteries and clear lung fields. 
Lung ventilation and perfusion scanning revealed 
multiple perfusion defects consistent with pulmonary 
emboli. Echocardiography revealed tricuspid regurgi- 
tation with gross dilatation of the right atrium 
and ventricle. The left heart appeared normal. Right 
heart cardiac catheterization demonstrated raised 
pulmonary artery pressure (108 mmHg systolic, 
3 1 mmHg diastolic) with no evidence of interatrial or 
interventricular shunt. Pulmonary arterial hyperten- 
sion secondary to recurrent thromboembolism was 
diagnosed. Plasma BNP and ANP concentrations 
measured after lying for 30 min were 35.8 pmol I- ’ 
and 32.3 pmol l- ’ respectively, at which time the 
oxygen saturation was 92%. 
These case reports are interesting for two main 
reasons. Firstly, both plasma BNP and ANP appear 
elevated in patients with pulmonary arterial hyper- 
tension compared to healthy subjects. Secondly, low- 
ering pulmonary vascular resistance with nifedipine 
did not acutely affect plasma BNP levels in a patient 
with primary pulmonary hypertension. 
The sites and mechanisms of BNP release have not 
been fully elucidated in man. Despite in vitro evidence 
of co-secretion of ANP and BNP from cardiac myo- 
cytes (7) the main source of BNP appears to be via 
constitutive release from cardiac ventricular tissue 
(2). This is in contrast to ANP which is released 
mainly from stored granules in atria1 tissue. Measur- 
ing BNP-mRNA and BNP concentrations in human 
cardiac tissue, Hosoda et al. (8) showed that although 
the atrium expresses BNP gene, a considerable 
amount of BNP-mRNA is present in the ventricle (8). 
Indeed, when tissue weight is taken into account, the 
total content of BNP-mRNA in the ventricles repre- 
sents 77% of the whole heart, whereas the total 
amount of ANP-mRNA in the ventricle is only 3%. 
Furthermore, they showed that there was an equal 
distribution of BNP gene in both right and left 
ventricles in normal human cardiac tissue obtained at 
autopsy. Our finding that plasma BNP is elevated in 
patients with isolated pulmonary arterial hyperten- 
sion supports the hypothesis that it can be released 
from the right side of the heart. It is interesting to 
speculate whether our observations may have patho- 
physiological implications. If BNP is natriuretic, 
it might act in conjunction with ANP to counteract 
the sodium retention often found in these patients. 
Furthermore, studies have shown that ANP (9) and, 
more recently, BNP (10) are capable of inducing 
relaxation of the pulmonary vasculature. This might 
suggest that alterations of BNP and ANP release may 
be of pathophysiological importance in limiting the 
level of pulmonary hypertension seen in patients with 
pulmonary arterial hypertension. 
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